معرفی
Dr. Deanna Taylor is a Senior Lecturer and optometrist at City St George's, University of London. She joined City in 2014 after completing her PhD and a post-doctoral research fellowship. Her academic career is complemented by clinical practice, as she continues to work part-time in independent optometric practice on weekends.
Dr. Taylor earned her PhD from City, University of London (2014-2018) and her BSc (Hons) in Optometry with First Class Honours from Aston University in 2011. Her doctoral research focused on 'Everyday visual function and the visual experience in dry age-related macular degeneration.'
Her primary research interests center around measurement of quality of life and visual function in age-related eye disease, particularly age-related macular degeneration (AMD). Dr. Taylor's work bridges clinical optometry and academic research, with a focus on understanding how visual impairment affects daily living and developing better assessment tools for visual function. She has made significant contributions to the MACUSTAR consortium, which is developing clinical endpoints for intermediate AMD trials.
Dr. Taylor's recent publications demonstrate a consistent focus on patient-centered outcomes in ophthalmology, with increasing emphasis on quality of life assessments, novel visual function testing methods, and understanding patient experiences with AMD and emerging treatments. Her work shows particular expertise in developing and validating patient-reported outcome measures for eye disease.
- George Giles Postgraduate Research Prize from the College of Optometrists (2017)
- Master's Medal from the Worshipful Company of Spectacle Makers (2017)
- Alcon Scholarship (2014)
- Association of Optometrists Prize from Aston University (2011)
- Applied Vision Prize from Aston University (2010)
Dr. Taylor serves on the Editorial Board of Optometry in Practice (2018-present) and is an active member of professional organizations including the College of Optometrists and the Association of Optometrists. Her work with the MACUSTAR consortium has positioned her at the forefront of developing clinical trial endpoints for intermediate AMD, contributing to both the scientific understanding of the disease and potential future treatments.
